196 related articles for article (PubMed ID: 11092869)
1. Sensitive genetic screen for protease activity based on a cyclic AMP signaling cascade in Escherichia coli.
Dautin N; Karimova G; Ullmann A; Ladant D
J Bacteriol; 2000 Dec; 182(24):7060-6. PubMed ID: 11092869
[TBL] [Abstract][Full Text] [Related]
2. An Escherichia coli expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavir.
Melnick L; Yang SS; Rossi R; Zepp C; Heefner D
Antimicrob Agents Chemother; 1998 Dec; 42(12):3256-65. PubMed ID: 9835523
[TBL] [Abstract][Full Text] [Related]
3. Co-evolution of drug resistance and broadened substrate recognition in HIV protease variants isolated from an Escherichia coli genetic selection system.
Koivisto JM; Poulsen NR; Larsen BS; Weibull MGM; Stein A; Doro F; Winther JR; Lindorff-Larsen K; Willemoës M
Biochem J; 2022 Feb; 479(4):479-501. PubMed ID: 35089310
[TBL] [Abstract][Full Text] [Related]
4. Negative regulation of adenylate cyclase gene (cya) expression by cyclic AMP-cyclic AMP receptor protein in Escherichia coli: studies with cya-lac protein and operon fusion plasmids.
Kawamukai M; Kishimoto J; Utsumi R; Himeno M; Komano T; Aiba H
J Bacteriol; 1985 Nov; 164(2):872-7. PubMed ID: 2997135
[TBL] [Abstract][Full Text] [Related]
5. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.
Côté HC; Brumme ZL; Harrigan PR
J Virol; 2001 Jan; 75(2):589-94. PubMed ID: 11134271
[TBL] [Abstract][Full Text] [Related]
6. Establishment of a new cell line inducibly expressing HIV-1 protease for performing safe and highly sensitive screening of HIV protease inhibitors.
Fuse T; Watanabe K; Kitazato K; Kobayashi N
Microbes Infect; 2006 Jun; 8(7):1783-9. PubMed ID: 16815068
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
Hoetelmans RM; Meenhorst PL; Mulder JW; Burger DM; Koks CH; Beijnen JH
Pharm World Sci; 1997 Aug; 19(4):159-75. PubMed ID: 9297727
[TBL] [Abstract][Full Text] [Related]
8. Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes.
Velazquez-Campoy A; Vega S; Freire E
Biochemistry; 2002 Jul; 41(27):8613-9. PubMed ID: 12093278
[TBL] [Abstract][Full Text] [Related]
9. Human immunodeficiency virus type 1 gag-protease fusion proteins are enzymatically active.
Kotler M; Arad G; Hughes SH
J Virol; 1992 Nov; 66(11):6781-3. PubMed ID: 1404618
[TBL] [Abstract][Full Text] [Related]
10. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors.
Rose RE; Gong YF; Greytok JA; Bechtold CM; Terry BJ; Robinson BS; Alam M; Colonno RJ; Lin PF
Proc Natl Acad Sci U S A; 1996 Feb; 93(4):1648-53. PubMed ID: 8643685
[TBL] [Abstract][Full Text] [Related]
11. The Haemophilus influenzae adenylate cyclase gene: cloning, sequence, and essential role in competence.
Dorocicz IR; Williams PM; Redfield RJ
J Bacteriol; 1993 Nov; 175(22):7142-9. PubMed ID: 8226661
[TBL] [Abstract][Full Text] [Related]
12. Rapid phenotypic assay for human immunodeficiency virus type 1 protease using in vitro translation.
Iga M; Matsuda Z; Okayama A; Sugiura W; Hashida S; Morishita K; Nagai Y; Tsubouchi H
J Virol Methods; 2002 Oct; 106(1):25-37. PubMed ID: 12367727
[TBL] [Abstract][Full Text] [Related]
13. Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo.
Ermolieff J; Lin X; Tang J
Biochemistry; 1997 Oct; 36(40):12364-70. PubMed ID: 9315877
[TBL] [Abstract][Full Text] [Related]
14. Autoprocessing of the HIV-1 protease using purified wild-type and mutated fusion proteins expressed at high levels in Escherichia coli.
Louis JM; McDonald RA; Nashed NT; Wondrak EM; Jerina DM; Oroszlan S; Mora PT
Eur J Biochem; 1991 Jul; 199(2):361-9. PubMed ID: 2070793
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
Zhang YM; Imamichi H; Imamichi T; Lane HC; Falloon J; Vasudevachari MB; Salzman NP
J Virol; 1997 Sep; 71(9):6662-70. PubMed ID: 9261388
[TBL] [Abstract][Full Text] [Related]
16. Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site.
Sardana VV; Schlabach AJ; Graham P; Bush BL; Condra JH; Culberson JC; Gotlib L; Graham DJ; Kohl NE; LaFemina RL
Biochemistry; 1994 Mar; 33(8):2004-10. PubMed ID: 8117657
[TBL] [Abstract][Full Text] [Related]
17. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
Wu X; Liu H; Xiao H; Kappes JC
Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
[TBL] [Abstract][Full Text] [Related]
18. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug.
Mammano F; Trouplin V; Zennou V; Clavel F
J Virol; 2000 Sep; 74(18):8524-31. PubMed ID: 10954553
[TBL] [Abstract][Full Text] [Related]
19. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
Leonis G; Steinbrecher T; Papadopoulos MG
J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
[TBL] [Abstract][Full Text] [Related]
20. Resistance to HIV protease inhibitors: a comparison of enzyme inhibition and antiviral potency.
Klabe RM; Bacheler LT; Ala PJ; Erickson-Viitanen S; Meek JL
Biochemistry; 1998 Jun; 37(24):8735-42. PubMed ID: 9628735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
